Related Experiment Video

Updated: May 29, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Protection of pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A

Muneki Hotomi1, Masamitsu Kono, Susan K Hollingshead

  • 1Department of Otolaryngology, Head and Neck Surgery, Wakayama Medical University, Wakayama, Japan. mhotomi@wakayama-med.ac.jp

Advances in Oto-Rhino-Laryngology
|August 26, 2011
PubMed

Insights

Maternal intranasal immunization with pneumococcal surface protein A (PspA) protects infants against fatal Streptococcus pneumoniae infections. This strategy induces protective antibodies, significantly extending offspring survival.

Area of Science:

  • Immunology
  • Microbiology
  • Pediatrics

Background:

  • Streptococcus pneumoniae causes significant childhood respiratory infections.
  • Infant pneumococcal infections pose a critical health challenge.
  • Existing prevention strategies for early childhood pneumococcal disease are limited.

Purpose of the Study:

  • To evaluate the efficacy of maternal immunization with pneumococcal surface protein A (PspA) in protecting infants against fatal pneumococcal infections.
  • To assess the induction of anti-PspA antibodies in mothers and offspring following intranasal PspA immunization.
  • To determine the impact of maternal PspA immunization on the survival rates of infant offspring challenged with S. pneumoniae.

Main Methods:

  • Female BALB/c mice were intranasally immunized with PspA and cholera toxin B (CTB).
  • Offspring from immunized mothers were challenged with S. pneumoniae to assess survival.
  • Serum samples were analyzed for anti-PspA-specific IgG antibody levels.

Main Results:

  • Anti-PspA-specific IgG antibodies were successfully induced in both mothers and their offspring.
  • Offspring from mothers immunized with PspA exhibited significantly extended survival times post-infection.
  • Maternal immunization demonstrated a protective effect against systemic fatal pneumococcal infections in early life.

Conclusions:

  • Maternal intranasal immunization with PspA is a promising approach for preventing infant pneumococcal infections.
  • This immunization strategy elicits protective immunity trans-generationally.
  • PspA-based maternal vaccination offers a potential new avenue for safeguarding young children against pneumococcal disease.

More Related Videos

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae09:12

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Published on: January 17, 2014

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...